Last checked at 7 Jan 2022 07:00
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Investor Presentation
H.C. Wainwright BIOCONNECT Virtual Conference
London, UK, 7 January, 2022: Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that Greg Madison, Chief Executive Officer of Shield, is scheduled to present virtually at the H.C. Wainwright BIOCONNECT Virtual Conference on 10 January, 2022. Please see presentation details below:
Date/Time: Virtual presentation available on-demand on Monday, 10 January, 2022 at 7:00 a.m. ET
Presenter: Greg Madison, Chief Executive Officer
To access the virtual presentation, sign up for 1x1 meetings, or for more information about the H.C. Wainwright BIOCONNECT Virtual Conference, please refer to the conference website at www.hcwevents.com/bioconnect/.
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Greg Madison, CEO | +44 (0) 191 511 8500 |
Hans-Peter Rudolf, CFO | |
Nominated Adviser and Joint Broker | |
Peel Hunt LLP | |
James Steel/Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore |
+44 (0)20 7220 0500 |
Financial PR & IR Advisor | |
Walbrook PR (UK Advisor) | |
Paul McManus/Lianne Applegarth/Alice Woodings
Investor Contact (US Advisor) | +44 (0)20 7933 8780 or shield@walbrookpr.com |
LifeSci Advisors, LLC John Mullaly
|
+1 617 429 3548 or jmullaly@lifesciadvisors.com |
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's proprietary lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia. The product has patent coverage until the mid-2030s. The Company recently launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx